MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago a ...

In its upcoming report, Boston Scientific (BSX) is predicted by Wall Street analysts to post quarterly earnings of $0.51 per share, reflecting an increase of 13.3% compared to the same period last year. Revenues are forecasted to be $3.59 billion, representing a year-over-year increase of 10.7%.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ini ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis o ...

Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2023 results on Jan 31, before the opening bell.In the last reported quarter, the company’s earnings per share of 50 cents exceeded the Zacks Consensus Estimate by 4.2%. BSX’s bottom line beat estimates in three of the trailing four quarters and missed on one occasion. The company has a trailing four-quarter earnings surprise of 4.34% on average.Factors at PlayWith U.S. hospitals reporting an increase in the number of pr ...

智通财经APP获悉，投行Baird表示，在经历了三年的表现不佳之后，预计医疗科技股将在2024年跑赢大盘，但对牙科和美容市场近期仍持谨慎态度。 这家投行指出，上周在旧金山举行的投资会议提振了医疗科技股，iShares US Medical Devices ETF在过去五天里上涨了2.8%，超过了标准普尔500指数1.6%的涨幅。 Baird对2024年医疗科技股的首选仍然是爱尔康(ALC.US)、史赛克(SYK.US)、库珀医疗(COO.US)、Axonics(AXNX.US)和波士顿科学(BSX.US)。 Baird在最近的一份报告中表示，医疗技术患者数量在第四季度似乎保持良好，尤其是髋关节/膝关节置换术、糖尿病设备、隐形眼镜、眼科产品、心血管和神经调节设备以及手术机器人的需求强劲。Baird在最近的一份报告中表示，提前公布财报的公司也超过了华尔街对第四季度收入的预期，“在很大程度上符合2024年的普遍预期，从而降低了即将发布的报告的风险。” Baird分析师补充道:“我们越来越感觉到，在未来几周的第四季度电话会议上，我们将听到Dentsply Sirona (XRAY.US)、Envista (NVST. ...

Johnson & Johnson (JNJ), Merck (MRK) and Boston Scientific (BSX) kicked off the year's biggest medical conference with a trio of splashy takeovers topping $3 billion in combined value.X Health care behemoth J&J is spending $2 billion to buy Ambrx (AMAM), Merck pledged to pay $680 million for Harpoon Therapeutics (HARP) and medtech player Boston Scientific (BSX) is coughing up $3.7 billion for Axonics (AXNX). Novartis (NVS) is also buying privately held Calypso Biotech for $250 million up front.The deals all ...

Shares of Axonics Inc. AXNX, -0.84% soared 19.2% toward a 13-month high in premarket trading Monday, after the medical technology company focused on treating urinary and bowel dysfunction announced an agreement to be acquired by Boston Scientific Corp. BSX, -0.02% in a cash deal with an equity value of about $3.7 billion. Under terms of deal, Boston Scientific will pay $71 for each Axonics shares outstanding, which represents a 23.3% premium to Friday’s closing price of $57.57. Boston Scientific’s stock ta ...

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per s ...

Key TakeawaysU.S. equities were heading to the end of 2023 with losses at midday, although the Dow, S&P 500, and Nasdaq are set to show big gains for the full year.Tesla shares dropped after the EV maker's new Cybertruck had its first accident.Boston Scientific said it believes U.S. regulators will approve its system to treat atrial fibrillation early next year. U.S. equities were lower at midday on this last trading day of 2023. The Dow, S&P 500, and Nasdaq were down, although all three are likely to end o ...

MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF), the only trial to study the use of PFA as frontline therapy in patients with this form of AF. Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate ...